News

Detecting cardiomyopathies in the magnetic field

The MagMa study by the DHZC, involving DZHK researchers, shows for the first time in a prospective study that radiation-free magnetocardiography can…

Read more

4th DZG Munich Day 2026: Health Research in Munich Working Together for the Medicine of Tomorrow

Scientific highlights, transdisciplinary research, and new collaborations will be the focus of DZG Munich Day on July 29, 2026. For the fourth time,…

Read more

Cannabinoid receptor identified as new target against atherosclerosis

The so-called cannabinoid receptor was originally discovered because active compounds from the cannabis plant bind to it. In fact, however, it belongs…

Read more

Autoantibodies in focus: New study investigates cardiac and vascular damage in post-COVID ME/CFS

Why do some people develop persistent exertion intolerance with cardiovascular symptoms following a SARS-CoV-2 infection? A research team at the DZHK…

Read more

Inflammatory processes link kidney and heart

Oxalic acid triggers inflammation that promotes both chronic kidney and cardiovascular disease, and could be an underestimated driver of inflammation…

Read more

DZHK Scientist Involved in Solving a Decades-Old Blood Clotting Mystery

Why don't dangerous clots normally form in our blood? What happens when this protective mechanism fails? An international research team, including…

Read more

Why some plaques become dangerous

A spatial analysis of proteins in human blood vessels shows why some deposits tear more easily. A team from the DZHK site in Munich reports on this in…

Read more

EU funding for innovative therapies in life-threatening circulatory shock

An international research consortium is investigating a new therapeutic approach to life-threatening circulatory shock. The EU project CURE-SHOCK is…

Read more

A hidden switch fine-tunes the heart’s elasticity

A team led by Michael Gotthardt, many of whose members are researchers at the German Centre for Cardiovascular Research (DZHK), has discovered a…

Read more

SGLT2 inhibitor effectively protects against heart failure in individuals with genetic risk

An analysis of the DECLARE-TIMI 58 trial shows that carriers of cardiomyopathy-related genes benefit disproportionately from dapagliflozin. The…

Read more